P-527 Results of a dose-finding study with short-schedule cisplatin (P) and vinorelbine (V) in non-small cell lung cancer (NSCLC): An attempt to improve feasibility and compliance

Zucali, Paolo Andrea; Parra, Hector J. Solo; Cavina, Raffaele; Latteri, F; Campagnoli, Elisabetta; Biancofiore, G.; Abbadessa, Giovanni; Ferrari, Benvenuto; Morenghi, Emanuela; Santoro, Armando

doi:10.1016/s0169-5002(03)92494-9

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, oral formulation offers greatest convenience in terms of patient's comfort, and ease of administration [13]. Recently, several studies have shown that vinorelbine combined with other chemotherapeutic agents is delivered safely twice a week in the treatment of breast cancer [14], high-grade lymphoma [15] and NSCLC [16].…”

Section: Introductionmentioning

confidence: 99%

Phase II trial of alternating intravenous and oral vinorelbine in combination with cisplatin in advanced non-small cell lung cancer

et al. 2007

Self Cite

View full text Add to dashboard Cite

Cisplatin-based chemotherapy is the standard treatment for advanced non-small cell lung cancer (NSCLC). Several platinum-based doublets have been tested in phase II/III trials with equivalent results in terms of tumour response and survival. Our study was designed to evaluate activity, tolerability and convenience of alternating intravenous (i.v.) and oral vinorelbine in combination with cisplatin in advanced NSCLC. Forty chemo-naive patients with stage IV or relapsed unresectable disease and good performance status were enrolled to receive i.v. cisplatin 40 mg/m(2) on days 1 and 2 plus i.v. vinorelbine 25 mg/m(2) on day 1, every 3 weeks. Oral vinorelbine 60 mg/m(2) was given at home on day 5, without checking of blood cell count. A total of 175 treatment cycles were delivered. The overall response rate was 30% (one complete, 11 partial responses). Median time to progression and overall survival were 5 and 10 months, respectively. The main toxicity was haematological, with grade 3-4 neutropenia observed in 75% of patients, without febrile neutropenia. Non-haematological toxicity was mild. This schedule of cisplatin and vinorelbine treatment showed a good toxicity profile and an efficacy similar to other standard regimens. Oral vinorelbine could be administered safely at home on day 5.

show abstract

Section: Introductionmentioning

confidence: 99%